Mok CC. Understanding lupus nephritis: Diagnosis, management, and treatment options. Int J Womens Health 2012; 4: 213-22.
Mok CC, Tang SS, To CH, Petri M. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: A comparison of three ethnic groups. Arthritis Rheum 2005; 52: 2774-82.
Bastian HM, Roseman JM, McGwin G Jr, et al. LUMINA Study Group. Lupus in minority populations: Nature vs nurture. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 2002; 11: 152-60.
Fernández M, Alarcón GS, Calvo-Alén J, et al. LUMINA Study Group. A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Rheum 2007; 57: 576-84.
Sánchez E, Rasmussen A, Riba L, et al. Impact of genetic ancestry and sociodemographic status on the clinical expression of systemic lupus erythematosus in American Indian-European populations. Arthritis Rheum 2012; 64: 3687-94.
Mok CC. Towards new avenues in the management of lupus glomerulonephritis. Nat Rev Rheumatol 2016; 12: 221-34.
Sarnak MJ. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 2003; 4: 11-7.
Mok CC, Kwok RC, Yip PS. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum 2013; 65: 2154-60.
Jolly M, Toloza S, Goker B, et al. Disease-specific quality of life in patients with lupus nephritis. Lupus 2018; 27: 257-64.
Hahn BH, McMahon MA, Wilkinson A, et al. American College of rheumatology. American college of rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012; 64: 797-808.
Bertsias GK, Tektonidou M, Amoura Z, et al. European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71: 1771-82.
Mok CC, Yap DY, Navarra SV, et al. Overview of lupus nephritis management guidelines and perspective from Asia. Nephrology (Carlton) 2014; 19: 11-20.
Mok CC, Ying KY, Yim CW, et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: A randomised controlled trial and long-term follow-up. Ann Rheum Dis 2016; 75: 30-6.
Liu Z, Zhang H, Liu Z, et al. Multitarget therapy for induction treatment of lupus nephritis: A randomized trial. Ann Intern Med 2015; 162: 18-26.
Mok CC, To CH, Yu KL, Ho LY. Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: A 12-month prospective study. Lupus 2013; 22: 1135-41.
Weidenbusch M, Römmele C, Schröttle A, Anders HJ. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant 2013; 28: 106-11.
Díaz-Lagares C, Croca S, Sangle S, et al. UK-BIOGEAS Registry. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts. Autoimmun Rev 2012; 11: 357-64.
Terrier B, Amoura Z, Ravaud P, et al. Club Rhumatismes et Inflammation. Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 2010; 62: 2458-66.
Rovin BH, Furie R, Latinis K, et al. LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64: 1215-26.
Mok CC. Biological and targeted therapies of systemic lupus erythematosus: Evidence and the state of the art. Expert Rev Clin Immunol 2017; 13: 677-92.
Mok CC. Emerging biological therapies for systemic lupus erythematosus. Expert Opin Emerg Drugs 2014; 19: 303-22.
Merrill JT, Wallace DJ, Wax S, et al. Efficacy and safety of atacicept in patients with systemic lupus erythematosus: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study. Arthritis Rheumatol 2018; 70: 266-76.
Furie R, Khamashta M, Merrill JT, et al. CD1013 Study Investigators. Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol 2017; 69: 376-86.
Mok CC. Treat-to-target in systemic lupus erythematosus: Are we there yet? Expert Rev Clin Pharmacol 2016; 9: 675-80.
Hemmingsen B, Lund SS, Gluud C, et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev 2013; 11: CD008143.
Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-62.
van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: Recommendations from an international task force. Ann Rheum Dis 2014; 73: 958-67.
van Vollenhoven R, Voskuyl A, Bertsias G, et al. A framework for remission in SLE: Consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis 2017; 76: 554-61.
Zen M, Iaccarino L, Gatto M, et al. Prolonged remission in Caucasian patients with SLE: Prevalence and outcomes. Ann Rheum Dis 2015; 74: 2117-22.
Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis 2016; 75: 1615-21.
ACCESS trial group. Treatment of lupus nephritis with abatacept: The abatacept and cyclophosphamide combination efficacy and safety study. Arthritis Rheumatol 2014; 66: 3096-104.
Liang MH, Schur PH, Fortin P, et al. The american college of rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006; 54: 421-32.
Dall’Era M, Cisternas MG, Smilek DE, et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol 2015; 67: 1305-13.
Mok CC, Ho LY, To CH, Chan KL. Factors associated with renal remission, relapse and long-term renal function decline in lupus nephritis treated with combined prednisolone and mycophenolate mofetil or tacrolimus. [abstract]. Arthritis Rheumatol 2015; 67(Suppl. 10): 1292-3.
Lertdumrongluk P, Somparn P, Kittanamongkolchai W, et al. Pharmacokinetics of mycophenolic acid in severe lupus nephritis. Kidney Int 2010; 78: 389-95.
Neumann I, Fuhrmann H, Fang IF, et al. Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil. Nephrol Dial Transplant 2008; 23: 3514-20.
Zahr N, Arnaud L, Marquet P, et al. Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. Arthritis Rheum 2010; 62: 2047-54.
Djabarouti S, Breilh D, Duffau P, et al. Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: An observational cohort study. Arthritis Res Ther 2010; 12: R217.
Tang C, Godfrey T, Stawell R, Nikpour M. Hydroxychloroquine in lupus: Emerging evidence supporting multiple beneficial effects. Intern Med J 2012; 42: 968-78.
Olsen NJ, Schleich MA, Karp DR. Multifaceted effects of hydroxychloroquine in human disease. Semin Arthritis Rheum 2013; 43: 264-72.
Pons-Estel GJ, Alarcón GS, McGwin G Jr, et al. Lumina Study Group. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum 2009; 61: 830-9.
Sisó A, Ramos-Casals M, Bové A, et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: Influence on outcomes and survival. Lupus 2008; 17: 281-8.
Alarcón GS, McGwin G, Bertoli AM, et al. LUMINA Study Group. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: Data from LUMINA, a multiethnic US cohort (LUMINA). Ann Rheum Dis 2007; 66: 1168-72.
Ruiz-Irastorza G, Egurbide MV, Pijoan JI, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006; 15: 577-83.
Griffin B, Lightstone L. Renoprotective strategies in lupus nephritis: Beyond immunosuppression. Lupus 2013; 22: 1267-73.